Multidrug therapy and evolution of antibiotic resistance: when order matters

Applied and Environmental Microbiology

Volumn 78, Issue 17, 2012, Pages 6137-6142

  Perron, Gabriel G ^a,b   Kryazhimskiy, Sergey ^a   Rice, Daniel P ^a   Buckling, Angus ^b,c  

^a HARVARD UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC-RESISTANT BACTERIA; COMBINATION THERAPY; DRUG RESISTANCE; HIGH COSTS; IN-VITRO; MULTIDRUG RESISTANCE; PATHOGENIC BACTERIUM; POPULATION DYNAMICS MODELS; PSEUDOMONAS AERUGINOSA; SUPPLY RATE;

ANTIBIOTICS; BACTERIA;

DRUG THERAPY;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIUM; DISEASE TREATMENT; DRUG; HEALTH WORKER; INFECTIVITY; PATHOGEN; POPULATION DYNAMICS; PUBLIC HEALTH;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; DRUG INTERACTION; EVOLUTION; MUTATION; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BIOLOGICAL EVOLUTION; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; MUTATION; PSEUDOMONAS AERUGINOSA;

PSEUDOMONAS AERUGINOSA;

EID: 84866147770     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01078-12     Document Type: Article

References (42)

1. Albert TJ, et al. 2005. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nat. Methods 2:951-953.
2. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
3. Andes D, Anon J, Jacobs MR, Craig WA. 2004. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab. Med. 24:477-502.
4. Bal AM, Kumar A, Gould IM. 2010. Antibiotic heterogeneity: from concept to practice, p 81-91. In Bush K (ed), Antimicrobial therapeutics reviews, vol 1213. Wiley-Blackwell, Malden, MA.
5. Beardmore RE, Peña-Miller R. 2010. Antibiotic cycling versus mixing: the difficulties of using mathematical models to definitively quantify their relative merits. Math. Biosci. Eng. 7:923-933.
6. Beardmore RE, Peña-Miller R. 2010. Rotating antibiotics selects optimally against antibiotic resistance, in theory. Math. Biosci. Eng. 7: 26.
7. Bell G. 2008. Selection: the mechanism of evolution. Oxford University Press, Oxford, United Kingdom.
8. Bennett KM, et al. 2007. Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J. Trauma 63:307-311.
9. Bergstrom CT, Lo M, Lipsitch M. 2004. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc. Natl. Acad. Sci. U. S. A. 101:13285-13290.
10. Bhusal Y, Shiohira CM, Yamane N. 2005. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 26:292-297.
11. Bonhoeffer S, Wiesch PA, Kouyos RD. 2010. Rotating antibiotics does not minimize selection for resistance. Math. Biosci. Eng. 7:919-922.
12. Campbell EA, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
13. Chiba N, Rao BV, Rademaker JW, Hunt RH. 1992. Metaanalysis of the efficacy of antibiotic-therapy in eradicating Helicobacter-pylori. Am. J. Gastroenterol. 87: 1716-1727.
14. Daniels M, Hill AB. 1952. Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials. Br. Med. J. 1:1162-1168.
15. Eber MR, Laxminarayan R, Perencevich EN, Malani A. 2010. Clinical and economic outcomes attributable to health care-associated sepsis and pneumonia. Arch. Intern. Med. 170:347-353.
16. Gagneux S, et al. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946.
17. Gould IM, van der Meer JWM (ed). 2007. Antibiotic policies: fighting resistance, 1st ed. Springer Science+Business Media, LLC, New York, NY.
18. Hauser AR. 2007. Antibiotics basics for clinicians: choosing the right antibacterial agent. Lippincott Williams & Wilkins, Baltimore, MD.
19. Kerr KG, Snelling AM. 2009. Pseudomonas aeruginosa: a formidable and ever-present adversary. J. Hosp. Infect. 73:338-344.
20. Kouyos RD, zur Wiesch PA, Bonhoeffer S. 2011. Informed switching strongly decreases the prevalence of antibiotic resistance in hospital wards. PLoS Comput. Biol. 7:e1001094. doi:10.1371/journal.pcbi.1001094.
21. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10(Suppl 12): S122-S129.
22. MacLean RC, Hall AR, Perron GG, Buckling A. 2010. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet. 11:405-414.
23. Ochman H, Lawrence JG, Grolsman EA. 2000. Lateral gene transfer and the nature of bacterial innovation. Nature 405:299-304.
24. Palumbi SR. 2001. Humans as the world's greatest evolutionary force. Science 293:1786-1790.
25. Pearson A. 2009. Historical and changing epidemiology of healthcareassociated infections. J. Hosp. Infect. 73:296-304.
26. Perron GG, Bell G, Quessy S. 2008. Parallel evolution of multidrugresistance in Salmonella enterica isolated from swine. FEMS Microbiol. Lett. 281:17-22.
27. Perron GG, Gonzalez A, Buckling A. 2008. The rate of environmental change drives adaptation to an antibiotic sink. J. Evol. Biol. 21:1724-1731.
28. Perron GG, Gonzalez A, Buckling A. 2007. Source-sink dynamics shape the evolution of antibiotic resistance and its pleiotropic fitness cost. Proc. Biol. Sci. 274:2351-2356.
29. Perron GG, Hall AR, Buckling A. 2010. Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. Am. Nat. 176:303-3011.
30. Perron GG, Lee AE, Wang Y, Huang WE, Barraclough TG. 2012. Bacterial recombination promotes the evolution of multidrug-resistance in functionally diverse populations. Proc. Biol. Sci. 279:1477-1484.
31. Pinheiro JC, Bates DM. 2000. Mixed-effects models in S and S-PLUS. Springer, New York, NY.
32. Radman M. 1975. SOS repair hypothesis: phenomenology of an inducible DNArepair which is accompanied by mutagenesis. Basic Life Sci. 5A: 355-367.
33. Reinhardt A, et al. 2007. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob. Agents Chemother. 51:1341-1350.
34. Sandiumenge A, et al. 2006. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J. Antimicrob. Chemother. 57:1197-1204.
35. Schrag SJ, Perrot V, Levin BR. 1997. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. R. Soc. Biol. Sci. B 264:1287-1291.
36. Sharma D, Cukras AR, Rogers EJ, Southworth DR, Green R. 2007. Mutational analysis of S12 protein and implications for the accuracy of decoding by the ribosome. J. Mol. Biol. 374:1065-1076.
37. Stover CK, et al. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964.
38. Trindade S, et al. 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS Genet. 5:e1000578. doi:10.1371/journal.pgen.1000578.
39. Ward H, Perron GG, Maclean RC. 2009. The cost of multiple drug resistance in Pseudomonas aeruginosa. J. Evol. Biol. 22:997-1003.
40. Warren DK, et al. 2004. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit. Care Med. 32:2450-2456.
41. Yeh P, Tschumi AI, Kishony R. 2006. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38:489-494.
42. zur Wiesch PA, Kouyos R, Engelstãdter J, Regoes RR, Bonhoeffer S. 2011. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 11:236-247.